Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from MacroGenics, Inc., Puma Biotechnology Inc., and Seattle Genetics Inc.
Meeting Key Unmet Clinical Needs in HER2-Positive Breast Cancer: Aligning the Data With Strategy to Improve Patient Outcomes
Fontainebleau Miami Beach
4441 Collins Avenue
Miami Beach, FL 33140
Meeting Key Unmet Clinical Needs in HER2-Positive Breast Cancer: Aligning the Data With Strategy to Improve Patient Outcomes Overview
Survival outcomes for patients with HER2-positive (HER2+) breast cancer have improved with the advent of HER2-targeted therapies. However, many important clinically unmet needs remain in the early and advanced HER2+ disease settings, including determination of how to best apply HER2-targeted agents and other therapeutic approaches based upon individual patient- and disease-related factors. Guidelines for assessment of HER2 status continue to evolve, and it is vital for practicing clinicians to be familiar with recent changes in order to make informed management decisions. Resistance to HER2 targeting remains another clinical challenge, and exploration of newer treatment options to help address this obstacle remains an area of active clinical investigation. Recent evidence has also shed light on treatment sequencing, as well as strategies to mitigate potential treatment-associated adverse events for patients with HER2+ breast cancer, and busy clinicians should be aware of this evidence to optimize outcomes.
To help you to meet these challenges, this compelling program will feature the perspectives of clinical experts in the management of patients with HER2+ breast cancer who will explore various aspects of patient assessment and treatment. Clinical case scenarios will be reviewed to help contextualize recent evidence pertaining to the safety and efficacy of different treatment options for patients with early-stage and advanced disease. After the faculty panel discussion, audience members are encouraged to share questions from their own experience with the panel to further promote engagement around clinically challenging situations.
Benefits of Participation:
Participating in this exciting, interactive CME event provides you with the opportunity to:
- Gain insights into recent studies that may improve outcomes for your patients with HER2+ breast cancer
- Enhance your understanding of recent guidelines pertaining to assessment of HER2 status
- Present your challenging patient case questions to the expert faculty
- Network with your colleagues and leading clinical experts in the management of breast cancer
Acknowledgment of Commercial Support
This activity is supported by educational grants from MacroGenics, Inc., Puma Biotechnology, Inc., and Seattle Genetics Inc.
This educational activity is directed toward medical oncologists, surgeons, pathologists, and fellows attending the 36th Annual Miami Breast Cancer Conference®. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.
Upon successful completion of this activity, you should be better prepared to:
- Evaluate clinical trial data regarding current and emerging therapeutics for HER2+ breast cancer, including adjuvant and metastatic settings
- Explain recent updates to guidelines for HER2 testing, and improved risk stratification in HER2+ breast cancer
- Identify strategies to mitigate adverse events associated with therapeutics used for the treatment of HER2+ breast cancer
- Place emerging data into the context of clinical scenarios for improved outcomes in treating patients with HER2+ breast cancer
Program Chair for Meeting Key Unmet Clinical Needs in HER2-Positive Breast Cancer: Aligning the Data With Strategy to Improve Patient Outcomes
Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
You must be logged in to PER to register for this meeting
Or Register for PER now